News Releases Joni Henderson 9/21/26 Joni Henderson 9/21/26 C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer's Trust to Improve Alzheimer's Disease Diagnosis Read More Joni Henderson 9/17/26 Joni Henderson 9/17/26 ‘Live Long and Prosper’: Nimoy-Knight Foundation Selects C2N’s CEO andCo-Founder for Prestigious Award Following Alzheimer’s Disease Blood Test FDA Clearance Read More Joni Henderson 8/20/26 Joni Henderson 8/20/26 FDA Clears C2N Diagnostics’ PrecivityAD2® —First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40 Read More Joni Henderson 7/28/26 Joni Henderson 7/28/26 United Kingdom Researchers Integrate C2N’s PrecivityAD2® Blood Test Into the Alzheimer’s Disease Diagnostic Care Pathway Read More Joni Henderson 7/9/26 Joni Henderson 7/9/26 Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation Read More Joni Henderson 6/1/26 Joni Henderson 6/1/26 C2N Diagnostics and SouthGenetics Partner to Enable Broader Access to Precivity® Blood Tests for Alzheimer’s Disease Assessment in Latin America, Caribbean Read More Joni Henderson 3/19/26 Joni Henderson 3/19/26 C2N Highlights First Use of its eMTBR-Tau243 Plasma Assay in EVOKE/EVOKE+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic AD Read More Joni Henderson 3/11/26 Joni Henderson 3/11/26 C2N Diagnostics Enters South Korean Market Through Partnership withBeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests toHelp Doctors Diagnose Alzheimer’s Disease Read More Joni Henderson 11/24/25 Joni Henderson 11/24/25 C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests toHelp Diagnose Alzheimer’s Disease Read More Joni Henderson 11/13/25 Joni Henderson 11/13/25 C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization Read More Joni Henderson 10/1/25 Joni Henderson 10/1/25 C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test Read More Joni Henderson 9/25/25 Joni Henderson 9/25/25 New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients Read More Joni Henderson 9/3/25 Joni Henderson 9/3/25 Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease Read More Joni Henderson 8/25/25 Joni Henderson 8/25/25 C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older Read More Joni Henderson 8/7/25 Joni Henderson 8/7/25 C2N Announces Major Global Expansion, Adds Six New International Partners Read More Joni Henderson 7/15/25 Joni Henderson 7/15/25 C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias Read More Joni Henderson 3/12/25 Joni Henderson 3/12/25 Samsung Invests in C2N Diagnostics Read More Joni Henderson 2/24/25 Joni Henderson 2/24/25 C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom Read More Joni Henderson 1/31/25 Joni Henderson 1/31/25 Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease Read More Joni Henderson 1/28/25 Joni Henderson 1/28/25 First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology Read More Older Posts
Joni Henderson 9/21/26 Joni Henderson 9/21/26 C2N Diagnostics Expands Global Partnerships in United Kingdom on World Alzheimer’s Day, Joins Cambridge Cognition and The Alzheimer's Trust to Improve Alzheimer's Disease Diagnosis Read More
Joni Henderson 9/17/26 Joni Henderson 9/17/26 ‘Live Long and Prosper’: Nimoy-Knight Foundation Selects C2N’s CEO andCo-Founder for Prestigious Award Following Alzheimer’s Disease Blood Test FDA Clearance Read More
Joni Henderson 8/20/26 Joni Henderson 8/20/26 FDA Clears C2N Diagnostics’ PrecivityAD2® —First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40 Read More
Joni Henderson 7/28/26 Joni Henderson 7/28/26 United Kingdom Researchers Integrate C2N’s PrecivityAD2® Blood Test Into the Alzheimer’s Disease Diagnostic Care Pathway Read More
Joni Henderson 7/9/26 Joni Henderson 7/9/26 Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease Evaluation Read More
Joni Henderson 6/1/26 Joni Henderson 6/1/26 C2N Diagnostics and SouthGenetics Partner to Enable Broader Access to Precivity® Blood Tests for Alzheimer’s Disease Assessment in Latin America, Caribbean Read More
Joni Henderson 3/19/26 Joni Henderson 3/19/26 C2N Highlights First Use of its eMTBR-Tau243 Plasma Assay in EVOKE/EVOKE+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic AD Read More
Joni Henderson 3/11/26 Joni Henderson 3/11/26 C2N Diagnostics Enters South Korean Market Through Partnership withBeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests toHelp Doctors Diagnose Alzheimer’s Disease Read More
Joni Henderson 11/24/25 Joni Henderson 11/24/25 C2N Diagnostics Awarded Rigorous New York State Department of Health Permit, Expanding Ability to Provide Its Blood Tests toHelp Diagnose Alzheimer’s Disease Read More
Joni Henderson 11/13/25 Joni Henderson 11/13/25 C2N Diagnostics and WashU Medicine Teams Receive Prestigious Award from Human Proteome Organization Read More
Joni Henderson 10/1/25 Joni Henderson 10/1/25 C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test Read More
Joni Henderson 9/25/25 Joni Henderson 9/25/25 New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients Read More
Joni Henderson 9/3/25 Joni Henderson 9/3/25 Dynamic Growth Leads C2N Diagnostics to Expand St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease Read More
Joni Henderson 8/25/25 Joni Henderson 8/25/25 C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older Read More
Joni Henderson 8/7/25 Joni Henderson 8/7/25 C2N Announces Major Global Expansion, Adds Six New International Partners Read More
Joni Henderson 7/15/25 Joni Henderson 7/15/25 C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias Read More
Joni Henderson 2/24/25 Joni Henderson 2/24/25 C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom Read More
Joni Henderson 1/31/25 Joni Henderson 1/31/25 Study Highlights How C2N’s PrecivityAD2™ Blood Biomarker Test Use Improves Clinical Decision-Making in the Evaluation for Alzheimer’s Disease Read More
Joni Henderson 1/28/25 Joni Henderson 1/28/25 First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology Read More
